SEC Company Response from Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802) (KPTI) — Nov 1, 2013
Karyopharm Therapeutics Inc. (KPTI) (CIK 0001503802)
Date: Nov. 1, 2013 · CIK: 0001503802 · Accession: 0001104659-13-080012
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-191584
Letter
Re: Karyopharm Therapeutics Inc.
November 1, 2013
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1 (SEC File No. 333-191584)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Karyopharm Therapeutics Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., New York City time, on November 5, 2013 or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed approximately 2,133 copies of the Preliminary Prospectus dated October 28, 2013 (the “Preliminary Prospectus”) through the date hereof, to underwriters, dealers, institutions and others.
In connection with the Preliminary Prospectus distribution for the above-reference issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement as promulgated by Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of page intentionally left blank]
Very truly yours,
MERRILL LYNCH, PIERCE, FENNER & SMITH
Show Raw Text
CORRESP 1 filename1.htm November 1, 2013 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Karyopharm Therapeutics Inc. Registration Statement on Form S-1 (SEC File No. 333-191584) Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Karyopharm Therapeutics Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., New York City time, on November 5, 2013 or as soon thereafter as practicable. Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed approximately 2,133 copies of the Preliminary Prospectus dated October 28, 2013 (the “Preliminary Prospectus”) through the date hereof, to underwriters, dealers, institutions and others. In connection with the Preliminary Prospectus distribution for the above-reference issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement as promulgated by Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Remainder of page intentionally left blank] Very truly yours, MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED LEERINK SWANN LLC By: MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED By: /s/ Michele A. H. Allong Name: Michele A. H. Allong Title: Authorized Signatory For themselves and as Representatives of the other Underwriters. [Signature Page to Karyopharm Therapeutics Inc. S-1 Acceleration Request]